Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study

World Journal of Gastroenterology

Volumn 21, Issue 10, 2015, Pages 3013-3019

  Stasi, Cristina ^a,b   Piluso, Alessia ^a   Arena, Umberto ^a   Salomoni, Elena ^a   Montalto, Paolo ^c   Monti, Monica ^a   Boldrini, Barbara ^a   Corti, Giampaolo ^a   Marra, Fabio ^a   Laffi, Giacomo ^a   Milani, Stefano ^a   Zignego, Anna Linda ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Health Agency of Tuscany Region   (Italy)

^c Ospedale SS Cosma e Damiano   (Italy)

Author keywords

Antiviral therapy; Chronic hepatitis C; Fibrosis; Liver stiffness; Sustained virological response

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PROLINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ATTRIBUTABLE RISK; CHILD PUGH SCORE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL IMMUNOLOGY; COMPARATIVE STUDY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIGESTIVE TRACT PARAMETERS; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER PARENCHYMA; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PATIENT RISK; PILOT STUDY; PROGNOSIS; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; RANK SUM TEST; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; VIROLOGY; AGED; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; ECHOGRAPHY; ELASTOGRAPHY; GENETICS; HEPACIVIRUS; LIVER; MIDDLE AGED; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ELASTICITY IMAGING TECHNIQUES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROLINE; PROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84924942452     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i10.3013     Document Type: Article

References (32)

1. Pinzani M. Liver fibrosis. Springer Semin Immunopathol 1999; 21: 475-490 [PMID: 10945037]
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218 [PMID: 15690074 DOI: 10.1172/JCI200524282]
3. Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009; 50: 1045-1055 [PMID: 19676125 DOI: 10.1002/hep.23130]
4. Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, Yoshihara M, Dore GJ. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010; 53: 616-623 [PMID: 20619475 DOI: 10.1016/j.jhep.2010.04.024]
5. El Raziky M, Attia D, El Akel W, Shaker O, Khatab H, Abdo S, Elsharkawy A, Esmat G. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment. Arab J Gastroenterol 2013; 14: 94-98 [PMID: 24206736 DOI: 10.1016/j.ajg.2013.08.005]
6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
7. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293 [PMID: 8690394]
8. Associazione Italiana Per Lo Studio Del Fegato. Parere dell'Associazione Italiana per lo Studio del Fegato (AISF) sull'uso della triplice-terapia (Peg-IFN Ribavirina inibitore delle proteasi di prima generazione) per il trattamento dei pazienti con epatite cronica da HCV genotipo 1. Available from: URL: http://www.webaisf.org/media/16360/position-paper-definitivo.pdf
9. Nishiura T, Watanabe H, Ito M, Matsuoka Y, Yano K, Daikoku M, Yatsuhashi H, Dohmen K, Ishibashi H. Ultrasound evaluation of the fibrosis stage in chronic liver disease by the simultaneous use of low and high frequency probes. Br J Radiol 2005; 78: 189-197 [PMID: 15730982]
10. Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio E, Miyaki T, Joh T. Noninvasive evaluation of hepatic fibrosis in hepatitis C virus-infected patients using ethoxybenzyl-magnetic resonance imaging. J Gastroenterol Hepatol 2013; 28: 1032-1039 [PMID: 23432660 DOI: 10.1111/jgh.12181]
11. Stasi C, Arena U, Vizzutti F, Zignego AL, Monti M, Laffi G, Corti G, Pinzani M. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool? Dig Liver Dis 2009; 41: 863-866 [PMID: 19482565 DOI: 10.1016/j.dld.2009.04.002]
12. Ichikawa S, Motosugi U, Ichikawa T, Sano K, Morisaka H, Enomoto N, Matsuda M, Fujii H, Araki T. Magnetic resonance elastography for staging liver fibrosis in chronic hepatitis C. Magn Reson Med Sci 2012; 11: 291-297 [PMID: 23269016]
13. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83: 127-134 [PMID: 19443053 DOI: 10.1016/j.antiviral.2009.04.002]
14. Arima Y, Kawabe N, Hashimoto S, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Kobayashi K, Ichino N, Osakabe K, Nishikawa T, Okumura A, Ishikawa T, Yoshioka K. Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. Hepatol Res 2010; 40: 383-392 [PMID: 20236358]
15. Macías J, del Valle J, Rivero A, Mira JA, Camacho A, Merchante N, Pérez-Camacho I, Neukam K, Rivero-Juárez A, Mata R, Torre-Cisneros J, Pineda JA. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. J Antimicrob Chemother 2010; 65: 2204-2211 [PMID: 20656678 DOI: 10.1093/jac/dkq272]
16. Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. J Gastroenterol Hepatol 2010; 25: 964-969 [PMID: 20546451 DOI: 10.1111/j.1440-1746.2009.06194.x]
17. Martinez SM, Foucher J, Combis JM, Métivier S, Brunetto M, Capron D, Bourlière M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, de Lédinghen V. Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS One 2012; 7: e47715 [PMID: 23082200 DOI: 10.1371/journal.pone.0047715]
18. Stasi C, Arena U, Zignego AL, Corti G, Monti M, Triboli E, Pellegrini E, Renzo S, Leoncini L, Marra F, Laffi G, Milani S, Pinzani M. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis 2013; 45: 840-843 [PMID: 23660078 DOI: 10.1016/j.dld.2013.03.023]
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649 [PMID: 4541913]
20. Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. J Viral Hepat 2013; 20: e107-e114 [PMID: 23490377 DOI: 10.1111/jvh.12017]
21. Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Lédinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-408 [PMID: 16020491]
22. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-973 [PMID: 17255218 DOI: 10.1136/gut.2006.111302]
23. Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, Brunetto MR. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14: 360-369 [PMID: 17439526 DOI: 10.1111/j.1365-2893.2006.00811.x]
24. Arena U, Vizzutti F, Abraldes JG, Corti G, Stasi C, Moscarella S, Milani S, Lorefice E, Petrarca A, Romanelli RG, Laffi G, Bosch J, Marra F, Pinzani M. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57: 1288-1293 [PMID: 18448567 DOI: 10.1136/gut.2008.149708]
25. Sagir A, Erhardt A, Schmitt M, Häussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008; 47: 592-595 [PMID: 18098325]
26. Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, Fruhwirth R, Marcellini M, Pinzani M. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442-448 [PMID: 18563842 DOI: 10.1002/hep.22376]
27. Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, Wedemeyer H, Bahr MJ. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int 2009; 29: 1500-1506 [PMID: 19732330 DOI: 10.1111/j.1478-3231.2009.02100.x]
28. Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G, Piazzolla V, Badea R, Laffi G, Marra F, Mangia A, Pinzani M. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology 2013; 58: 65-72 [PMID: 23447459 DOI: 10.1002/hep.26343]
29. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
30. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
31. Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol 2013; 58: 479-487 [PMID: 23183529 DOI: 10.1016/j.jhep.2012.11.020]
32. Tural C, Planas R. [Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects]. Enferm Infecc Microbiol Clin 2013; 31 Suppl 3: 19-25 [PMID: 24063899 DOI: 10.1016/S0213-005X(13)70120-4]